PFE

7 Dividend Stocks to Buy at a 52-Week Low 

By Chris Markoch, InvestorPlace Contributor
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.

3 Blue-Chip Stocks to Buy for High Total Returns by 2025

By Faisal Humayun, InvestorPlace Contributor
These undervalued blue-chip stocks represent fundamentally strong companies with healthy cash flow visibility.

3 Value Stocks to Buy at 52-Week Low in February

By Muslim Farooque, InvestorPlace Contributor
Optimistic in 2024? Here are three of the best value stocks amid the market's cautious revival, offering strong upside potential.

3 Blue-Chip Stocks to Buy at a 52-Week Low in February

By Chris Markoch, InvestorPlace Contributor
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.

3 Biotech Stocks to Buy on the Dip: February 2024 

By Chris Markoch, InvestorPlace Contributor
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

7 Retirement Stocks to Buy at 52-Week Lows

By Ian Bezek, InvestorPlace Contributor
Investors are pricing in a substantial number of interest rate cuts in the coming months, which has led to a surge in stock prices. And…

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024

By Muslim Farooque, InvestorPlace Contributor
Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements

3 Sleeper Stocks to Buy for the Next Bull Run: February 2024

By Muslim Farooque, InvestorPlace Contributor
Embark on a savvy investing as we uncover three sleeper stocks and chart their stellar long-term potential to perform.

3 Magnificent Stocks to Buy on the Dip: February 2024

By Josh Enomoto, InvestorPlace Contributor
While it’s a relative rarity because price generally discounts everything, that doesn’t mean you can’t find stocks to buy on dip. With thousands upon thousands…

Million-Dollar Bets: 7 Stocks to Buy Before They Blast Off

By Yiannis Zourmpanos, InvestorPlace Contributor
In the stock market, identifying promising investment opportunities is a pursuit that demands attention to detail and solid foresight.

Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market

By David Moadel, InvestorPlace Contributor
Pfizer is in Wall Street's doghouse, but don't despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.

Listen to Wall Street and Buy These 3 Stocks Now

By Josh Enomoto, InvestorPlace Contributor
To be blunt, buying a Wall Street recommended stock can be a mixed bag. While we trust experts in say the legal and medical fields,…

3 Standout Stocks That Crushed Q4 Earnings Estimates

By Joel Baglole, InvestorPlace Contributor
These three stocks crushing Q4 earnings are on the rise after the companies behind them closed the year with a bang.

7 High-Yield Dividend Stocks With High-Upside Potential

By Josh Enomoto, InvestorPlace Contributor
High-yield dividend stocks with potential for upside gains is essentially the Tony Robbins of market opportunities. Robbins gives you a big smile, a warm hug…

3 Dividend Stocks to Buy and Hold for Long-Term Income in 2024

By Charles Munyi, InvestorPlace Contributor
The critical nature of services provided by these dividend stocks for long-term income support generation of predictable cashflows.

3 Healthcare Stocks at 52-Week Lows: Buy or Bye?

By Alex Sirois, InvestorPlace Contributor
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.

3 Stocks to Sell Before Their Earnings Reports Disappoint in 2024

By Joel Baglole, InvestorPlace Contributor
Here are three stocks to sell before earnings numbers are released during this challenging earnings season.

The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs

By Stavros Tousios, InvestorPlace Contributor
Next gen biotech stocks such as Pfizer, Exscientia, and GSK leverage AI to drive biotech breakthroughs, shaping the future of the industry.

7 Over-Hyped Stocks to Sell Before They Plunge

By Louis Navellier and the InvestorPlace Research Staff
Maybe you’ve fallen for the hype and it's time to think about which stocks to sell. It’s easy to get excited about a stock with…
Load More